Skip to content
The Role of the Family Practice Provider in the Diagnosis, Management, and Referral Evaluation (ID: i764a-1)
*
1.
After participating in this activity, how confident are you in the management of patients with AS in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
2.
How many years have you been in practice?
(Required.)
>21
11-20
1-10
<1
*
3.
How many patients with AS do you manage?
(Required.)
1 to 25
26 to 50
51 to 100
100+
I am not directly involved in patient care
*
4.
Please select the option that best describes your practice setting.
(Required.)
Academic medical center
Community hospital or medical center
VA, DOD or other government
Managed Care
Research
Pharmaceutical industry
*
5.
How committed are you to making changes in your practice based on your participation in this activity?
(Required.)
Very committed
Committed
Neutral
Not committed
I do not plan to make changes
If not committed or do not plan to make changes, please indicate reason
*
6.
Which of the following best describes the impact of this activity on your performance?
(Required.)
I gained new strategies/skills/information I can apply to my area of practice
I need more information before I can change my practice
My practice is already consistent with the information presented
This activity will not change my practice
*
7.
Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.
(Required.)
Knowledge of the epidemiology of AS
Knowledge regarding the pathophysiology of AS and role of HLA-B27
Knowledge of the signs and symptoms of AS
Knowledge of the risk factors for AS and progression of the disease
Knowledge of average delays in diagnosis, diagnostic challenges, and the role of the family physician in early detection
An understanding of AS diagnostic considerations, imaging, screening, and when to refer to a rheumatologist
An understanding of AS disease monitoring tools and current guideline recommendations
An understanding of pharmacological treatments for AS, including NSAIDs, TNF-a inhibitors, and IL-17 monoclonal antibodies
Knowledge of outcomes from recent clinical trials, such as the MEASURE trials of secukinumab and COAST trials of ixekizumab
Knowledge of ongoing phase 3 trials for patients with AS
*
8.
What barriers do you see to making changes in your practice?
(Required.)
Lack of knowledge regarding evidence-based strategies
Lack of convincing evidence to warrant change
Lack of time/resources to consider change
Insurance, reimbursement or legal issues
Conflicting guidelines or evidence
Patient compliance and/or patient resource barriers
Other (please explain)
*
9.
After participating in today’s activity, I am now able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Recognize the role of family practice in the timely diagnosis of AS
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Apply current guideline recommendations to the management of ankylosing spondylitis
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
10.
M. Elaine Husni, MD MPH, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
11.
The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Addressed my most pressing questions
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Promoted improvements or quality in health care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias or influence
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
12.
As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
13.
Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for AS or related disease states.
14.
If you indicated that you perceived commercial bias or influence, please describe.